Prospective Grant of Exclusive License: Development of Therapeutics To Treat Obesity, Type 2 Diabetes, Fatty Liver Disease, and Liver Fibrosis in Humans, 66015 [2015-27454]

Download as PDF Federal Register / Vol. 80, No. 208 / Wednesday, October 28, 2015 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Prospective Grant of Exclusive License: Development of Therapeutics To Treat Obesity, Type 2 Diabetes, Fatty Liver Disease, and Liver Fibrosis in Humans National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Public Health Service, HHS. ACTION: Notice. AGENCY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7, that the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to practice the following inventions embodied in the following patent applications, entitled ‘‘CB1 receptor mediating compounds’’: mstockstill on DSK4VPTVN1PROD with NOTICES SUMMARY: 1. U.S. Provisional Patent Application No.: 61/991,333 HHS Ref. No.: E–140–2014/0–US–01 Filed: May 09, 2014 2. PCT Application No.: PCT/US2015/029946 HHS Ref. No.: E–140–2014/0–PCT–02 Filed: May 08, 2015 3. U.S. Provisional Patent Application No.: 61/725,949 HHS Ref. No.: E–282–2012/0–US–01 Filed: November 13, 2012 4. PCT Application No.: PCT/US2013/069686 HHS Ref. No.: E–282–2012/0–PCT–02 Filed: November 12, 2013 5. U.S. Patent Application No.: 14/442,383 HHS Ref. No.: E–282–2012/0–US–03 Filed: May 12, 2015 6. Canadian Patent Application No.: 2889697 HHS Ref. No.: E–282–2012/0–CA–04 Filed: April 27, 2015 7. European Patent Application No.: 13802153.0 HHS Ref. No.: E–282–2012/0–EP–05 Filed: June 01, 2015 8. Indian Patent Application No.: 3733/ DELNP/2015 HHS Ref. No.: E–282–2012/0–IN–06 Filed: May 01, 2015 9. Japanese Patent Application No.: 2015– 542015 HHS Ref. No.: E–282–2012/0–JP–07 Filed: May 11, 2015 10. Chinese Patent Application No.: 201380069389.9 HHS Ref. No.: E–282–2012/0–CN–08 Filed: July 3, 2015 11. U.S. Provisional Application No.: 62/ 171,179 HHS Ref. No.: E–282–2012/1–US–01 Filed: June 04, 2015 to Inversago Pharma Inc., (‘‘Inversago’’), a company incorporated under the laws of Canada having an office in at least Montreal-Ouest, Quebec, Canada. The VerDate Sep<11>2014 19:16 Oct 27, 2015 Jkt 238001 patent rights in these inventions have been assigned to the United States of America. This license may be worldwide. The field of use may be related to ‘‘Development of therapeutics to treat obesity, type 2 diabetes, fatty liver disease and liver fibrosis in humans.’’ Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before November 12, 2015 will be considered. ADDRESSES: Requests for copies of the patent application, patents, inquiries, comments, and other materials relating to the contemplated exclusive license should be directed to: Patrick McCue, Ph.D., Senior Licensing and Patenting Manager, Technology Advancement Office, The National Institute of Diabetes and Digestive and Kidney Diseases, 12A South Drive, Bethesda, MD 20892, Telephone: (301) 435–5560; Email: patrick.mccue@nih.gov. A signed confidentiality non-disclosure agreement will be required to receive copies of any patent applications that have not been published by the United States Patent and Trademark Office or the World Intellectual Property Organization. 66015 Dated: October 19, 2015. Anna Z. Amar, Acting Deputy Director, Technology Advancement Office, National Institute of Diabetes and Digestive and Kidney, Diseases, National Institutes of Health. [FR Doc. 2015–27454 Filed 10–27–15; 8:45 am] BILLING CODE 4140–01–P DATES: This technology, and its corresponding patent applications, is directed to methods of treating obesity and associated diseases such as type 2 diabetes, hepatic steatosis, and liver fibrosis by administering an agent that reduces appetite, body weight, and insulin resistance. This technology may be useful as a means for treating obesity and metabolic syndrome without serious adverse neuropsychiatric side effects. The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 404.7. The prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.7. Properly-filed and complete competing applications for a license in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552. SUPPLEMENTARY INFORMATION: PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 DEPARTMENT OF HOMELAND SECURITY Coast Guard [Docket No. USCG–2015–0805] National Offshore Safety Advisory Committee Coast Guard, DHS. Notice of Federal Advisory Committee meeting. AGENCY: ACTION: The National Offshore Safety Advisory Committee and its Subcommittee will hold a public meeting in Katy, TX to discuss the safety of operations and other matters affecting the offshore oil and gas industry. These meetings are open to the public. DATES: Subcommittees of the National Offshore Safety Advisory Committee will meet on Wednesday, November 18, 2015 from 1 p.m. to 4 p.m. and the full Committee will meet on Thursday, November 19, 2015, from 8:30 a.m. to 4:30 p.m. (All times are Central Standard Time). These meetings may end early if the Committee has completed its business, or they may be extended based on the number of public comments. ADDRESSES: The meetings will be held at the Det Norske Veritas GL conference facility located at 1400 Ravello Drive, Katy, TX 77449. For information on facilities or services for individuals with disabilities, or to request special assistance at the meetings, contact the individuals listed in FOR FURTHER INFORMATION CONTACT section, as soon as possible. To facilitate public participation, we are inviting public comment on the issues to be considered by the Committee as listed in the ‘‘Agenda’’ section below. Written comments may be submitted using the Federal eRulemaking Portal at https:// www.regulations.gov. If your material cannot be submitted using https:// www.regulations.gov, contact the person in the FOR FURTHER INFORMATION CONTACT section of this document for alternate instructions. Instructions: All submissions received must include the words ‘‘Department of SUMMARY: E:\FR\FM\28OCN1.SGM 28OCN1

Agencies

[Federal Register Volume 80, Number 208 (Wednesday, October 28, 2015)]
[Notices]
[Page 66015]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-27454]



[[Page 66015]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License: Development of 
Therapeutics To Treat Obesity, Type 2 Diabetes, Fatty Liver Disease, 
and Liver Fibrosis in Humans

AGENCY: National Institutes of Diabetes and Digestive and Kidney 
Diseases, National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 
part 404.7, that the National Institutes of Health, Department of 
Health and Human Services, is contemplating the grant of an exclusive 
patent license to practice the following inventions embodied in the 
following patent applications, entitled ``CB1 receptor mediating 
compounds'':

1. U.S. Provisional Patent Application No.: 61/991,333
HHS Ref. No.: E-140-2014/0-US-01
Filed: May 09, 2014

2. PCT Application No.: PCT/US2015/029946
HHS Ref. No.: E-140-2014/0-PCT-02
Filed: May 08, 2015

3. U.S. Provisional Patent Application No.: 61/725,949
HHS Ref. No.: E-282-2012/0-US-01
Filed: November 13, 2012

4. PCT Application No.: PCT/US2013/069686
HHS Ref. No.: E-282-2012/0-PCT-02
Filed: November 12, 2013

5. U.S. Patent Application No.: 14/442,383
HHS Ref. No.: E-282-2012/0-US-03
Filed: May 12, 2015

6. Canadian Patent Application No.: 2889697
HHS Ref. No.: E-282-2012/0-CA-04
Filed: April 27, 2015

7. European Patent Application No.: 13802153.0
HHS Ref. No.: E-282-2012/0-EP-05
Filed: June 01, 2015

8. Indian Patent Application No.: 3733/DELNP/2015
HHS Ref. No.: E-282-2012/0-IN-06
Filed: May 01, 2015

9. Japanese Patent Application No.: 2015-542015
HHS Ref. No.: E-282-2012/0-JP-07
Filed: May 11, 2015

10. Chinese Patent Application No.: 201380069389.9
HHS Ref. No.: E-282-2012/0-CN-08
Filed: July 3, 2015

11. U.S. Provisional Application No.: 62/171,179
HHS Ref. No.: E-282-2012/1-US-01
Filed: June 04, 2015

to Inversago Pharma Inc., (``Inversago''), a company incorporated under 
the laws of Canada having an office in at least Montreal-Ouest, Quebec, 
Canada. The patent rights in these inventions have been assigned to the 
United States of America. This license may be worldwide. The field of 
use may be related to ``Development of therapeutics to treat obesity, 
type 2 diabetes, fatty liver disease and liver fibrosis in humans.''

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
November 12, 2015 will be considered.

ADDRESSES: Requests for copies of the patent application, patents, 
inquiries, comments, and other materials relating to the contemplated 
exclusive license should be directed to: Patrick McCue, Ph.D., Senior 
Licensing and Patenting Manager, Technology Advancement Office, The 
National Institute of Diabetes and Digestive and Kidney Diseases, 12A 
South Drive, Bethesda, MD 20892, Telephone: (301) 435-5560; Email: 
patrick.mccue@nih.gov. A signed confidentiality non-disclosure 
agreement will be required to receive copies of any patent applications 
that have not been published by the United States Patent and Trademark 
Office or the World Intellectual Property Organization.

SUPPLEMENTARY INFORMATION: This technology, and its corresponding 
patent applications, is directed to methods of treating obesity and 
associated diseases such as type 2 diabetes, hepatic steatosis, and 
liver fibrosis by administering an agent that reduces appetite, body 
weight, and insulin resistance. This technology may be useful as a 
means for treating obesity and metabolic syndrome without serious 
adverse neuropsychiatric side effects.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404.7. The prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR part 404.7.
    Properly-filed and complete competing applications for a license in 
response to this notice will be treated as objections to the 
contemplated license. Comments and objections submitted in response to 
this notice will not be made available for public inspection and, to 
the extent permitted by law, will not be released under the Freedom of 
Information Act, 5 U.S.C. 552.

    Dated: October 19, 2015.
Anna Z. Amar,
Acting Deputy Director, Technology Advancement Office, National 
Institute of Diabetes and Digestive and Kidney, Diseases, National 
Institutes of Health.
[FR Doc. 2015-27454 Filed 10-27-15; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.